Langerhans cells (LC) 
Introduction
Dendritic cells (DC) are special subsets of antigen presenting cells characterized by their potent abilities to initiate antigen-specific immune responses (reviewed in Refs 1 and 2). Accumulating lines of evidence now indicate that immunologically naive T cells can be activated most efficiently or even exclusively by DC. Members of the DC family have been identified not only in lymphoid organs (eg spleen, lymph nodes and thymus), but also in virtually all tested non-lymphoid tissues. For example, the outermost layer of skin (ie epidermis) is covered by a fine network of Langerhans cells (LC). Resident LC in normal skin are equipped with the properties required for incorporating and processing exogenous antigens. Upon exposure to proinflammatory signals, LC migrate from the epidermis to the draining lymph nodes (LN) and at the same time they acquire other properties (eg elevated surface expression of MHC class II and costimulatory molecules) that are required for effective activation of naive T cells. Thus, LC at the environmental interface are specialized for capturing exogenous antigens and they mature into potent T cell stimulators by the time they reach the draining LN, suggesting their involvement in the induction of immune responses to skin-relevant antigens. 3 In fact, LC have been shown not only to initiate protective immunity against tumors and infectious microbes (viruses, bacteria and even parasites), but also to play pathogenic roles in the onset of autoimmune disorders and allergic reactions to environmental antigens. [4] [5] [6] [7] [8] [9] [10] [11] Our central hypothesis is that one can regulate the magnitudes, types, and/or directions of immune responses in skin by manipulating the function of LC. Working with long-term DC lines, termed 'XS' series, established from the epidermis of newborn mice, 12, 13 we have developed three DC manipulation protocols. First, the mature DC line XS106, when transfected transiently with cDNA encoding a model antigen, α1-antitrypsin (AAT) and administered back into syngeneic A/J mice, induced potent immune responses to AAT. 14 This implies that antigen-specific immune responses are readily inducible by direct transfection of LC. Second, when transfected transiently with the IL-4 cDNA and loaded with a protein antigen, keyhole limpet hemocyanin (KLH), XS106 DC induced T helper 2 (Th2)-skewed immune responses to KLH in A/J mice. 15 This implies that the type of immune responses can be altered by introducing a selected cytokine gene into LC. Finally, XS106 DC were converted into 'killer' DC by transfection with CD95L (Fas ligand) cDNA and neomycin-resistant gene, followed by G418 selection and limiting dilution.
(OVA) and contact hypersensitivity responses to a chemical hapten, dinitrofluorobenzene (DNFB), were suppressed in A/J mice by administration of the resulting killer XS106 DC clones pulsed with OVA and DNFB, respectively. This implies that the direction of immunological outcome (ie clonal expansion versus apoptosis of antigen-reactive T cells) can be controlled by introducing a death ligand cDNA into LC. Although these results validate our central hypothesis that LC function can be altered by genetic manipulation, the above protocols that require a stable DC line are not readily applicable to human patients. Therefore, the purpose of this study was to determine whether one can induce LC-targeted gene expression in situ without affecting their potentials to home to the draining LN and undergo maturational changes.
By subtracting a cDNA library constructed from an immature DC line XS52 with mRNAs isolated from a macrophage line J774, we have isolated several novel genes that are expressed selectively by DC. 17 One of these genes was found to encode a novel type II membraneintegrated polypeptide of 209 amino acids containing a single carbohydrate recognition domain and was, thus, designated as DC-specific lectin-2 or dectin-2.
18 Dectin-2 mRNA was expressed abundantly in the XS52 DC line, but not in any of the tested non-DC lines. Moreover, dectin-2 mRNA expression in the epidermal compartment was observed almost exclusively in the population expressing MHC class II (IA) molecules (ie LC). We interpreted these observations to suggest that a putative promoter of the dectin-2 gene may provide an ideal tool for driving LC-targeted gene expression in situ. Here we report in vitro and in vivo transcriptional activities of a 3.2 kb 5Ј flanking fragment of the mouse dectin-2 gene and a LC-targeted in situ gene therapy format.
Results

In vitro transcriptional activities of dectin-2 promoter
To test transcriptional activities of the putative dectin-2 promoter, we introduced the 3.2 kb 5Ј flanking fragment isolated from the mouse dectin-2 gene upstream of the Luc coding sequence in the pGL3 plasmid without additional transcriptional control elements (pDec2-Luc). As shown in Figure 1a , significant Luc expression was observed in the XS52 DC line after transfection with pDec2-Luc as compared with the baseline Luc activities after transfection with a promoter-less control Luc construct (pGL3-Luc). On the other hand, the magnitude of Luc activities driven by the dectin-2 promoter was rather minimal compared with the robust Luc expression observed with a SV40 promoter-driven Luc construct (pSV40-Luc). Nevertheless, these results document the ability of our dectin-2 promoter to drive the expression of exogenous gene in DC.
To compare relative transcriptional activities of dectin-2 promoter in various cell types, we transfected nine different cell lines in parallel with pDec2-Luc and pGL3-Luc and calculated the relative expression units by dividing the Luc activities with pDec2-Luc by the baseline Luc activities with pGL3-Luc. As shown in Figure 1b , the highest Luc expression was observed in the XS52 DC line, the cell line from which the dectin-2 cDNA was originally cloned. The mature DC line XS106 also exhibited rela- tively high Luc expression. Only modest Luc expression was detected in the J774 macrophage line, which was used as a substraction partner for cloning the dectin-2 gene. Likewise, dectin-2 promoter showed minimal, if any, transcriptional activities in the EL4 thymoma line, J558 B cell line, or P7-1 B cell hybridoma clone, suggesting that dectin-2 promoter is transcriptionally active in DC, but not in other leukocyte subsets.
Corroborating our observations that dectin-2 mRNA expression was detected almost exclusively within an IA + population in mouse epidermis, 18 striking differences were noted in the transcriptional activities of dectin-2 promoter between epidermal-derived DC lines (XS52 and XS106) versus other skin-derived cell lines, including the Pam 212 keratinocyte line, 7-17 dendritic epidermal T cell (DETC) line (derived from resident epidermal γδ T cells), and NS47 fibroblast line (Figure 1b) . Based on these observations, we hypothesized that LC-targeted gene expression might be achievable by delivering pDec2-Luc construct to the skin, preferably within the epidermal compartment.
In vivo transcriptional activities of dectin-2 promoter
In the next set of experiments, we administered the pSV40-Luc plasmid to the shaved abdominal skin of mice using the gene gun under several different conditions to optimize the delivery protocol. Under the current setting (300 helium psi, 1.6 micron gold microcarriers, 0.5 mg gold/shot, and 1 g DNA/shot) with the BioRad Helios System (BioRad, Hercules, CA, USA), we observed uniform distributions of gold particles primarily in the epidermis without evidence of major tissue destruction (data not shown). When pDec2-Luc was delivered under these conditions, significant Luc activities were detected in the whole skin specimens harvested from the bombarded sites at 24 h (Figure 2a ). It is to be emphasized that the relative Luc activities induced by pDec2-Luc plasmid were modest compared with those induced by pSV40-Luc (0.05 to 0.3% in six independent experiments). Only minimal Luc expression was induced by the promoterless control construct (pGL3-Luc). Importantly, the majority of the skin-associated Luc activities was recovered from the epidermis, documenting our ability to target the gene expression primarily in the epidermal compartment ( Figure 2b ). Taken together, these results indicate that dectin-2 promoter exhibits significant, albeit relatively low, transcriptional activities in the epidermis of living animals.
LC specificity of dectin-2 promoter-driven gene expression
To identify the cell types expressing the transgene, we constructed EGFP plasmids with the dectin-2 promoter (pDec2-EGFP) or the CMV promoter (pCMV-EGFP). When pDec2-EGFP was delivered into skin, EGFP expression was detected primarily in the epidermal compartment ( Figure 3a , left top panel). EGFP appeared to be expressed by a minor cell population with dendritic morphology. It should be noted that all tissue samples were stained with anti-GFP antibodies followed by FITCconjugated secondary antibodies to maximize the detection limit, because EGFP expression levels were relatively modest especially with the dectin-2 promoter. pCMV-EGFP induced more abundant and uniform EGFP expression in basal and suprabasal layers in epidermis ( Figure 3a , left middle panel). In the whole mount epidermal sheet preparations, EGFP expression was detected in a minor population, again with dendritic morphology with the pDec2-EGFP plasmid, whereas it was detected more abundantly, especially around hair follicles, with the pCMV-EGFP plasmid (Figure 3a , right panels). When the epidermal sheet preparations were labeled with phycoerythrin (PE)-conjugated anti-IA monoclonal antibody (mAb), dectin-2 promoter-driven EGFP expression (green fluorescence) was detected in 10-15% of IA + epidermal cells (red fluorescence) seen as the cells showing yellow fluorescence signals (Figure 3b ). In contrast, CMV promoter-driven EGFP expression was observed mostly in IA-negative epidermal cells around hair follicles.
To determine the extent of LC specificity more quantitatively, we delivered pDec2-Luc plasmid and depleted Gene Therapy the IA + cells by anti-IA mAb plus complement (C') from the epidermal preparations before measuring Luc activities. As shown in Figure 3c , anti-IA mAb plus C' treatment reduced dectin-2 promoter-driven Luc activities more significantly (70% reduction; P Ͻ 0.001) than did the control treatment with isotype-matched IgG plus C'. Thus, we have concluded that dectin-2 promoter can be used to target the gene expression primarily to epidermal LC. While performing these experiments, we noticed two major limitations. First, the overall expression levels achieved with the dectin-2 promoter is relatively low, as compared with robust expression inducible by strong viral promoters (eg SV40 and CMV promoters). Second, only minor populations (10-15%) of the LC in the bombarded sites express the gene product at detectable levels. Nevertheless, our results document a unique, LC-specific tran-scriptional activity of the dectin-2 promoter in living animals.
LC migration and maturation
As shown in Figure 4a (left panel), strong Luc expression was detected in the skin 12 h after gene gun-mediated delivery of the pSV40-Luc, and the expression level remained relatively unchanged for up to 24 h, followed by sharp and dramatic decline at 48-72 h. With the dectin-2 promoter, Luc expression in skin declined more rapidly (P Ͻ 0.05) at 12-24 h (Figure 4a, right panel) . To determine whether this rapid reduction in skin-associated Luc activities reflects LC migration to the LN, pDec2-EGFP was administered to the abdominal skin and the draining LN were harvested at different time-points. Our effort to identify EGFP protein expression in LN was unsuccessful presumably due to low expression levels of EGFP and low frequencies of EGFP-transfected LC. As an alternative strategy, we sought to detect EGFP mRNA after amplification by RT-PCR. As shown in Figure 4b , EGFP mRNA, which was not detected at 24 h, became clearly detectable in the LN 3 days after gene gunmediated delivery of the pDec2-EGFP plasmid. EGFP mRNA expression remained detectable 7 days, but not 14 days, after bombardment. These results suggest that at least some of the LC expressing EGFP mRNA have migrated to the draining LN.
Upon exposure to proinflammatory stimuli, not only do LC migrate to LN, they also begin to exhibit characteristic features of mature DC, the features that are most apparent in LC after short-term culturing (ie 'cultured' LC). It has been reported that gene gun-mediated bombardment of gold particles and/or expression of an exogenous gene product trigger LC migration and maturation. [19] [20] [21] [22] In fact, gene gun-mediated delivery of SV40-Luc plasmid resulted in dynamic changes in surface densities of IA + epidermal cells (Figure 5a ). The densities began to decline on day 1, decreased most markedly on To assess maturational states of the LC that remained in the epidermis after bombardment, we examined their surface expression of IA molecules and T cell stimulatory capacity. LC isolated from gene gun-treated skin sites showed significant elevation of IA expression compared with LC isolated from nontreated sites (Figure 6a ). Similar up-regulation was observed after delivery of pSV40-Luc plasmid in all three independent experiments ( Figure  6b ) and even after bombardment of non-coated gold particles (Figure 6c ). Functional hallmark of LC maturation is the acquisition of a potent ability to stimulate immunologically naive T cells in primary mixed leukocyte reactions. LC freshly procured from nontreated skin exhibited only a modest, if any, ability to activate allogeneic T cells, whereas 'cultured' LC triggered robust T cell proliferation (Figure 6d ). Importantly, LC harvested from skin sites receiving pSV40-Luc induced significant T cell activation, signifying their functional maturation. Again, bombardment of gold particles alone was sufficient to elevate the T cell stimulatory capacity of LC (Figure 6e ). These observations, which are in agreement with previous reports, [19] [20] [21] [22] suggest that LC-targeted expression of an exogenous gene product (ie antigen) is accompanied by subsequent migration and maturation of antigen-bearing LC. This implies further that antigen-specific immune responses may be readily inducible by this protocol, ie LC-targeted genetic immunization.
Immuological outcome of dectin-2 promoter-driven gene expression
Using EGFP as a model antigen, we sought to determine whether LC-targeted EGFP gene expression would be sufficient to produce humoral and/or cellular immune responses. pCMV-EGFP or pDec2-EGFP plasmid was delivered into skin three times at weekly intervals, and serum and spleen samples were collected 1 week after the third vaccination. All five mice immunized with pCMV-EGFP showed significant humoral responses to EGFP as visualized by apparent immunoreactivity of serum samples to recombinant EGFP in immunoblot analysis (Figure 7a) . By marked contrast, no EGFP-reactive immunoglobulins were detected in any of the six animals receiving the pDec2-EGFP plasmid. Thus, it appeared that modest expression of Luc gene by LC was not sufficient to trigger humoral responses at detectable levels.
Unfortunately, cytotoxic T cell responses against EGFPtransduced targets were not detectable even in the positive control animals immunized with pCMV-EGFP plasmid, perhaps due to relatively low antigenicity of EGFP in mice. On the other hand, we were able to detect significant proliferative and cytokine responses of spleen cells to recombinant EGFP. Addition of EGFP to spleen cell cultures induced statistically significant (P Ͻ 0.05; triplicate cultures for each animal) elevation of 3 H-thymidine uptake in five out of five animals in the CMV-Luc panel and six out of six animals in the pDec2-EGFP panel (Figure 7b) . Moreover, the mean proliferative responses to EGFP were significantly (P Ͻ 0.05) greater than the mean baseline responses in the absence of EGFP in both panels. Likewise, addition of EGFP to spleen cell cultures Gene Therapy resulted in interferon-γ (IFNγ) secretion in all five mice immunized with pCMV-EGFP and in five out of six mice immunized with pDec2-EGFP. The mean IFNγ concentrations were significantly (P Ͻ 0.05) higher in EGFPstimulated culture supernatants than in control culture supernatants in both pCMV-EGFP and pDec2-EGFP panels. All tested spleen cell preparations were comparable with each other in terms of proliferation and IFNγ secretion after Con A stimulation (closed bars), validating that equivalent numbers of T cells were present in these preparations. Neither humoral nor cellular responses to EGFP were detected in any of the three control mice receiving vector alone (Figure 7a ) or other control animals (n = 5) receiving gold particles alone (data not shown). Thus, modest expression of an exogenous gene by relatively small numbers of LC was sufficient for the development of detectable cellular immune responses to the gene product.
two-paired Student's t test) are indicated by asterisks. (d) BALB/c epidermal cells isolated from nontreated skin (closed squares) or the pSV40-Luc inoculation sites 24 h after bombardment (closed triangles) were γ-irradiated and examined for their capacities to activate T cells isolated from allogeneic CBA mice. Epidermal cells that had migrated from the skin explant cultures during a 3-day period, ie 'cultured' LC, served as a positive control (closed circles
)
Discussion
In the present study we have isolated a putative transcriptional regulatory region of the mouse dectin-2 gene, which was originally cloned from the XS52 DC-derived cDNA library by subtraction with mRNAs isolated from the J774 macrophage line. 18 The dectin-2 promoter induced the expression of the Luc gene predominantly in DC lines (XS52 and XS106) among several tested cell lines, corroborating the dectin-2 mRNA expression profiles in these cell lines. 18 Gene gun-mediated delivery of the Dec2-Luc or Dec2-EGFP plasmid to the skin of living animals resulted in the expression of Luc or EGFP by some, but not all, IA + epidermal LC, validating the in vivo transcriptional activity, as well as cell type-specificity of the dectin-2 promoter. Based on these observations, we now propose a new concept that LC-targeted gene expression is achievable by gene gun-mediated delivery of plasmid DNA under the control of a DC-specific promoter.
We (SAJ) reported several years ago that both humoral and cellular immune responses are readily inducible by introducing plasmid DNA encoding antigen. 23 This strategy, now known as genetic immunization, is considered to represent a major breakthrough in the vaccine field (reviewed in . With respect to the role played by DC in genetic immunization, Condon et al 19 reported that GFP + LC became detectable in the draining LN following gene gun-mediated delivery of GFP plasmid, documenting the potential of transgene-expressing LC to migrate from the epidermis to LN. In bone marrow chimeric mice, immune responses inducible by genetic immunization were found to be restricted to the MHC haplotype of the transplanted bone marrow cells, but not to the haplotype of the recipient animals. 27, 28 Immune responses have been induced by administration of relatively small numbers of DC that were directly transfected in vitro with DNA encoding a model antigen. 14, 29 More recently, antigen-specific immune responses have been induced in rhesus macaques by inoculating transgeneexpressing CD34
+ DC progenitors. 30 Finally, induction of immune responses was interrupted by surgical removal of the bombarded skin sites, 31, 32 whereas significant immune responses were transferred to otherwise naive recipients by grafting the bombarded skin harvested from vaccinated animals. 31 Taken together, these obser- The dectin-2 promoter may be potentially used to induce LC-targeted expression of not only antigens, but also immunoregulatory molecules. For example, DC that are genetically engineered in vitro to overexpress IL-12, GM-CSF, TNFα, and/or CD40 ligand genes have been used to boost the magnitude of antitumor immunity. 34, 35 Alternatively, immune responses have been suppressed in an antigen-specific manner by CD95L-transfected 'killer' DC and by CTLA4-Ig-transfected 'tolerogenic' DC. 16, 36 Time-consuming and costly ex vivo DC manipulation processes remain a major technical hurdle preventing these potentially useful approaches from clinical application. Our technology of gene gun-mediated, LCtargeted gene expression system may move this field toward practical medicine.
One may construct transgenic animals using the dectin-2 promoter. In this regard, Brocker et al 37 have targeted the expression of MHC class II I-E molecules to DC by using a CD11c promoter and identified the role of DC in negative selection of thymocytes. We have recently constructed transgenic mice expressing the Luc gene under the control of dectin-2 promoter. Luc expression occurred in a DC-specific manner, with the highest expression observed in epidermal LC (Bonkobara et al, manuscript in preparation). DC-targeted transgenic mice may provide a unique experimental tool to uncover immunological functions of newly cloned genes in the post-genome era.
With respect to relative safety, none of the >300 animals receiving pDec2-EGFP or pDec2-Luc plasmid inoculation died during the experimental procedures (up to 5 weeks). Even those mice that received three repeated inoculations of pDec2-EGFP showed no apparent adverse effects. These observations suggest that dectin-2 promoter-driven plasmids can be administered repeatedly without causing acute side-effects. On the other hand, long-term safety, especially the risk for autoimmune responses, remains to be fully evaluated.
Toward clinical application of our LC-targeted gene therapy format, one must overcome several technical problems. First, the 3.2 kb fragment used in this study showed relatively low transcriptional activities even in DC. Luc expression with the dectin-2 promoter was minimal even in the XS52 DC line as compared with the robust expression inducible by the SV40 promoter. Further improvement of the transcriptional activities without affecting DC specificity is required for maximal expression of the transgene product. Second, transgene expression was detected only in a relatively small fraction of epidermal LC at the bombarded skin sites. Transfection efficiency may be improved by modifying the conditions for gene gun operation and/or the delivery device. Third, the cellular immune responses induced by LC-targeted genetic vaccine need to be further characterized. This will be achievable by full assessment of the number, phenotype and function of antigen-reactive T cells. Finally, dectin-2 promoter (cloned from mouse Gene Therapy genome) may not exhibit full transcriptional activities in human DC. Experiments are in progress in our laboratories to resolve these and other problems. Nevertheless, we believe that the present study provides a conceptual framework for the development of a DC-targeted, in situ gene therapy format, which may be used to regulate the magnitudes, types and directions of immune responses.
Materials and methods
Animals and cells BALB/c mice (6-8 weeks old, female) were purchased from Jackson Laboratory (Bar Harbor, ME, USA) or obtained form the pathogen-free breeding colony at the University of Texas Southwestern Medical Center. All the animal experiments were approved by the Institutional Review Board and conducted according to the guidelines from the National Institutes of Heath (NIH). The XS52 and XS106 lines are murine epidermal-derived DC lines and their phenotypic and functional properties are described elsewhere. [12] [13] [14] [15] [16] Both lines were maintained and expanded in complete RPMI 1640 supplemented with murine recombinant GM-CSF and NS fibroblast-conditioned medium. 38 The Pam 212 keratinocyte line 39 and the 7-17 DETC line 40 were maintained as described previously. 41 The J774 murine macrophage, EL4 murine thymoma, and J558 B cell lines were purchased from the American Tissue Type Collection.
DNA constructs
Genomic nucleotides for the dectin-2 gene were isolated from a genomic library prepared from BALB/c mouse (Clontech, Palo Alto, CA, USA) by hybridization with the cDNA for dectin-2 (GenBank accession number AF240357). 18 A phage clone containing a 3.2 kb of the 5Ј-flanking region was excised by PCR amplification with Expand Long Template PCR System (Roche Diagnostics, Indianapolis, IN, USA) using primers complementary to a 5Ј-end cloning site and a 3Ј-end sequence of 5Ј-untranslated region. The amplified nucleotide was subcloned into a plasmid vector, pGEM-7zf(-) (Promega, Madison, WI, USA) (pGEM-Dec2FR), and its nucleotide sequence was determined at both sense and anti-sense strands. The region containing a 5Ј-flanking region (nt -3176 to +1, with the mRNA initiation site being designated as +1) and a full 5Ј-untranslated region was excised by digestion of pGEM-Dec2FR with MluI and XhoI restriction enzymes and introduced upstream the Luc coding sequence in pGL3-basic (Promega) without transcriptional control elements (pDec2-Luc). The promoter-less pGL3-Luc and the pSV40-Luc (Promega) containing SV40 promoter and enhancer were used as negative and positive controls, respectively. The CMV promoter-driven EGFP expression vector (pCMV-EGFP) was purchased from Clontech. To construct the pDec2-EGFP plasmid, a nucleotide fragment containing an EGFP coding sequence and an SV40 poly A signal was excised from pCMV-EGFP by PCR and introduced into pGEM-Dec2FR using HindIII and BamHI sites.
Gene gun-mediated DNA delivery Luc plasmids (1 g DNA/10 6 cells) were delivered into various cell lines using the Biolistic Particle Delivery System (Du Pont Model PDS-1000, Wilmington, DE, USA)
